Get a reply from this employer — a resume and cover letter tailored to exactly what they’re hiring for.
UK W is seeking a highly motivated PhD scientist to lead the development of in vivo CAR-T cell generation using next-generation CRISPR and lipid nanoparticle delivery. You will work at the forefront of genome engineering, immunology, and translational cell therapy within an ERC-funded program.
Responsibilities include supervising junior researchers, designing experiments, and collaborating across disciplines to translate concepts into new therapeutic strategies.
Application deadline: 31/10/2026
Join a newly funded ERC research program at the forefront of genome engineering, lipid nanoparticle delivery, synthetic immunology, and next-generation cell therapy.
This position offers an exceptional opportunity to take a leading role in the development of innovative strategies for generating therapeutic CAR-T cells directly in vivo. The project aims to combine next-generation CRISPR technologies with advanced delivery systems, including lipid nanoparticles (LNPs), to enable the precise engineering of immune cells inside the human body.
The successful candidate will contribute to shaping a highly ambitious research program with significant translational potential while developing an independent scientific profile within a dynamic and collaborative research environment.
CAR-T cell therapy has transformed the treatment of selected hematological malignancies, but current approaches depend on complex, costly, and time-consuming ex vivo manufacturing.
Our ERC project aims to explore a fundamentally different paradigm: direct engineering of therapeutic immune cells in vivo.
To achieve this, we will combine next-generation genome-editing technologies with innovative concepts in immune-cell engineering and targeted delivery, with a particular interest in lipid nanoparticle-based approaches. A major focus will be on CRISPR 2.0 technologies that expand the possibilities of genome engineering beyond conventional DNA double-strand-break-based editing.
The successful candidate will play a central role in developing and translating these concepts into new strategies for the precise generation of CAR-T cells in vivo, including the development and evaluation of delivery strategies for genome-editing components.
We are looking for a creative, highly motivated scientist who enjoys developing new technologies and tackling ambitious biological questions.
Applicants should have:
Experience with lipid nanoparticle formulation and characterization, targeted LNP delivery, primary human T cells, CRISPR-based genome editing, CAR-T cells, flow cytometry, or other viral or non-viral delivery technologies would be particularly valuable.
Importantly, we do not expect candidates to already be experts in all aspects of the project. Previous experience with lipid nanoparticles is a strong plus, but not a prerequisite. We are looking for scientists with a strong experimental foundation, intellectual curiosity, and the ambition to expand into new technological areas.
In the case of a university degree from a non-EU country, a long version of the certificate evaluation from the Central Office for Foreign Education is required.
Remuneration is in accordance with the relevant collective agreements. Severely disabled applicants will be given preference if they are otherwise equally qualified.